摘要
目的低级别胶质瘤(LGG)患者异质性高、预后差异大,本研究利用特异性增强子调控的靶基因对LGG进行分型研究,以期为LGG临床治疗及相关机制研究提供参考。方法获取TCGA、CGGA数据库LGG患者数据;筛选特异性增强子调控的靶基因,利用K-means算法进行LGG分型,外部数据验证分型结果的稳定性;进一步比较各型间差异:GSVA比较基因通路活性、CIBERSORT算法比较免疫微环境、生存分析比较预后。结果筛选出50个特异性增强子调控的靶基因,LGG分型获得5个亚型,分别记为A1~A5;各型间基因通路活性、免疫微环境存在明显差异;A5亚型患者预后最差,A3和A4预后最好。结论本研究LGG分型获得5个亚型,分型结果稳定;各亚型在通路活性及临床特征等方面差异有统计学意义;研究结果可为患者精细化治疗和管理提供参考。
Objective Patients with lower grade glioma(LGG)have high heterogeneity and different prognosis.Thus,we identify the precise subtypes in LGG patients based on specific enhancers,to provide reference for clinical treatment and profound mechanism.Methods Data of LGG patients were downloaded from TCGA and CGGA databases.LGG subtypes were identified using K-means clustering after constructing the signatures regulated by specific enhancers and verified in independent external datasets.Further,GSVA was performed to analyze signal pathway,immune microenvironment estimation was performed with CIBERSORT algorithm,and overall survival was compared with survival analysis.Results Fifty target genes regulated by specific enhancers were screened,and 5 subtypes were obtained by LGG typing,which were denoted as A1-A5.There were significant differences in signal pathway activity and immune microenvironment among different types.A5 had the worst survival,while A3 and A4 had the best outcome.Conclusion Five LGG subtypes were obtained in this study,which are robust in external verification.There are significant differences in pathway activity and clinical characteristics associated with LGG subtypes.The results of this study can provide a reference for precise treatment and management of patients.
作者
严光灿
田伟
刘美娜
Yan Guangcan;Tian Wei;Liu Meina(Department of Biostatistics, Harbin Medical University, Harbin 150081, China)
出处
《中国医院统计》
2021年第6期502-507,共6页
Chinese Journal of Hospital Statistics
基金
国家自然科学基金(82173614)。
